EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Do patients with migraine and obesity receive different treatments? Insights from real‐world data

Keshet Pardo iD, Maor Mermelstein, Gal Tsur, Shlomit Yust-Katz

Headache: The Journal of Head and Face Pain · 2026-01 · 66 (1) · 88-95

DOI: 10.1111/head.70011 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2025-12-15. Written by Keshet Pardo and 3 co-authors. Institution: Neurology Department, Rabin Medical Center, Petach Tikva, Israel. Major MEDLINE topics: Migraine Disorders, Obesity, Tryptamines, Analgesics. Cited 2 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Patients with obesity often experience stigma in healthcare, which may lead to underdiagnosis or undertreatment. In the context of pain management, and migraine specifically, patients with obesity are more likely to receive both opioid and non‐opioid analgesics. However, little is known about their use of preventive treatments.

Methods

We conducted a large retrospective cohort study using propensity score matching for sex and age, utilizing data from the Clalit Health Services database in Israel. The study compared newly diagnosed patients with migraine with and without obesity, identified between June 2020 and June 2023. The comparison focused on prescriptions for migraine‐specific acute medication (triptans) and preventive migraine treatments.

Results

Our final analysis included 11,934 patients with migraine and obesity and 11,934 without obesity. Patients with obesity were more likely to have cardiovascular risk factors and psychiatric comorbidities. Patients with obesity were also more likely to receive acute treatment with triptans (adjusted odds ratio [aOR] 1.17, 95% confidence interval [CI] [1.11–1.23]), and preventive treatments such as topiramate (aOR 1.66, 95% CI [1.38–1.99]), gabapentinoids (aOR 1.30, 95% CI [1.13–1.50]), and duloxetine (aOR 1.42, 95% CI [1.18–1.70]), adjusting for comorbidities.

Conclusion

Our findings do not support the notion that patient with migraine and obesity are undertreated; instead, they show a modest increase in prescriptions for acute and some of the preventive medications. image

Subjects

MeSH terms (MEDLINE)

Migraine DisordersObesityTryptaminesAnalgesicsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedIsraelComorbidityTopiramateDatabases, Factual

Author keywords

healthcare stigmamigrainemigraine preventionobesitypain

Substances

TryptaminesAnalgesicsTopiramate

Authors and institutions

  • Neurology Department, Rabin Medical Center, Petach Tikva, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

ORCID profiles: Keshet Pardo

Cite

APA

Pardo, K., Mermelstein, M., Tsur, G., & Yust-Katz, S. (2026). Do patients with migraine and obesity receive different treatments? Insights from real‐world data. Headache: The Journal of Head and Face Pain, 66(1), 88-95. https://doi.org/10.1111/head.70011

Vancouver

Pardo K, Mermelstein M, Tsur G, Yust-Katz S. Do patients with migraine and obesity receive different treatments? Insights from real‐world data. Headache: The Journal of Head and Face Pain. 2026;66(1):88-95. doi:10.1111/head.70011

BibTeX
@article{Pardo2026,
  author = {Pardo, Keshet and Mermelstein, Maor and Tsur, Gal and Yust-Katz, Shlomit},
  title = {Do patients with migraine and obesity receive different treatments? Insights from real‐world data},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {1},
  pages = {88--95},
  doi = {10.1111/head.70011}
}
Start for free →